Tag Archives: Brazil

Industry Growth Slowdown in Brazil

By Hellen Berger. The Brazilian economy is being impacted by internal and external factors, and forecast figures are being quickly revised downwards. Market research released by Brazil’s Central Bank revised average analysts’ projections for economic growth in 2014 down to 0.70% from 0.90% four weeks earlier(1). In June 2014, the Hong Kong Trade Development Council […]
Posted in Global, Guest Blog | Also tagged , | Leave a comment

Is There Potential for Growth in Brazil’s Phytotherapic Drug Market?

It is well known that Brazil has an immense biodiversity and that the Amazon is the largest tropical rainforest in the world. Traditional Brazilian medicines include African elements, rooted on indigenous groups. Few pharmaceutical companies, however, know at what level phytotherapic drugs are commercialized in the country, how much regulation is imposed for herbal medicines, […]
Posted in Emerging Markets, Global, Guest Blog | Also tagged , , , | Leave a comment

Pharma Seizes Latin American Opportunities

Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years. And with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth, says a new report from GlobalData.
Posted in Emerging Markets, Market Access | Also tagged , , , , , | Leave a comment

Compliance Congress: Walking the Line

Pharma industry executives, FDA officials and Department of Justice attorneys speaking last week at CBI’s 11th annual Pharmaceutical Compliance Congress (PCC) offered solutions and threats to companies hoping to avoid enforcement actions.
Posted in Advertising, compliance, Emerging Markets, FDA, Global, Legal, Manufacturing, Marketing, People, Regulatory, Sales, Strategy, Technology | Also tagged , , , , , , , , , , , , | Leave a comment

BRIC Opportunities 2014

While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for the 2014 Industry Outlook, Reenita Das, Partner at Frost & Sullivan, says its now more important than […]
Posted in Global, Strategy | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta